IP Library Granted Patent US 9,895,386
Granted Patent B2
US 9,895,386 · App. 15/143,009 · Granted Feb 20, 2018

Antibiotic formulations, unit doses, kits, and methods

Inventors: Chatan Charan (San Jose, CA); Sarvajna Dwivedi (Redwood City, CA)
Assignee: BAYER INTELLECTUAL PROPERTY GMBH
A61K31/7036A61J1/065A61J1/1412A61K9/0019A61K9/0078A61K9/08A61K31/573A61K31/7034A61M11/001A61M16/04A61K9/19A61M2202/064
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,895,386
App. No.
15/143,009
Granted
Feb 20, 2018
Kind
B2
Abstract

An aqueous or powder composition includes anti-gram-negative antibiotic or salt thereof being present at an amount ranging from about 100 mg/ml to about 200 mg/ml. Another aqueous or powder composition includes anti-gram-positive antibiotic or salt thereof being present at a concentration ranging from about 0.6 to about 0.9 of the water solubility limit, at 25° C. and 1.0 atmosphere, of the anti-gram-positive antibiotic or salt thereof. Other embodiments include unit doses, kits, and methods.

Claims (16)

1. A method of producing a unit dose of an aqueous amikacin composition comprising:

a) preparing an amikacin solution by dissolving amikacin sulfate in preservative-free water by stirring;

b) adjusting the pH of the amikacin solution, if necessary, until the pH of the solution is between about 5.5 and 6.3; and

c) adding about 3 to 10 ml of the amikacin solution to a container in order to generate a unit dose; wherein the unit dose comprises a preservative-free liquid composition for aerosolization having a pH of about 5.5 to about 6.3 and a shelf life of at least two years at room temperature without the formation of precipitate, wherein the unit dose consists essentially of water and about 400 mg to about 750 mg amikacin, at a concentration of about 125 mg/ml; and wherein the unit dose has an osmolarity ranging from about 90 mOsmol/kg to about 500 mOsmol/kg and a potency of amikacin, from about 500 μg/mg to about 1100 μg/mg.

2. The method of claim 1 , wherein the container is in a nebulizer.

3. The method of claim 2 , wherein the nebulizer is a vibrating mesh nebulizer.

4. The method of claim 1 , wherein about 3 to 6 ml of the amikacin solution is added to the container in step c).

5. The method of claim 1 , wherein the container is an ampoule.

6. The method of claim 1 or 5 , wherein the container comprises a blow-fill seal.

7. The method of claim 1 , wherein the container comprises a vial.

8. The method of claim 1 , wherein the container comprises a glass bottle.

9. The method of claim 1 , wherein the rubber stopper is a rubber siliconized stopper.

10. A unit dose of an aqueous amikacin composition, wherein the unit dose is prepared according to a method comprising the steps of:

a) preparing an amikacin solution by dissolving amikacin sulfate in preservative-free water for injection by stirring;

b) adjusting the pH of the amikacin solution, if necessary, until the pH of the solution is between about 5.5 and 6.3; and

c) adding about 3 to 10 ml of the amikacin solution to a container in order to generate a unit dose; wherein the unit dose comprises a preservative-free liquid composition for aerosolization having a pH of about 5.5 to about 6.3 and a shelf life of at least two years at room temperature without the formation of precipitate, wherein the unit dose consists essentially of water and about 400 mg to about 750 mg amikacin, at a concentration of about 125 mg/ml; and wherein the unit dose has an osmolarity ranging from about 90 mOsmol/kg to about 500 mOsmol/kg and a potency of amikacin, from about 500 μg/mg to about 1100 μg/mg.

Continuity (5)
Continuation 13471126 · May 14, 2012
Division 12341780 · Dec 22, 2008
Continuation 11529128 · Sep 28, 2006
Provisional Application 60722564 · Sep 29, 2005
Related Publication 20160317562A1 · Nov 3, 2016